FDA Approves First Treatment for Individuals with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi recently announced that the U.S. FDA has approved Dupixent® to treat patients aged 12 years and older with eosinophilic esophagitis (EoE). With this approval, Dupixent becomes the first and only medicine specifically indicated to treat EoE in the United States. EoE is a chronic inflammatory disease driven by type 2 inflammation that damages the esophagus and prevents it from working properly. For people with EoE, swallowing even small amounts of food can be a painful and worrisome choking experience. Learn more here.